Get started
Author

Nicholas A. Squittieri

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
2019 · R. Dummer, A. Guminksi, et al. · British Journal of Dermatology · 199
PDF
A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma
2021 · Michael Migden, Aaron Farberg, et al. · Journal of Drugs in Dermatology · 49
PDF
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
2021 · Ralf Gutzmer, Carmen Loquai, et al. · Dermatology and Therapy · 26
PDF
Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial
2020 · John T Lear, Axel Hauschild, et al. · Clinical Cosmetic and Investigational Dermatology · 26
PDF
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis
2021 · Ralf Gutzmer, Caroline Robert, et al. · BMC Cancer · 24
PDF
Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial
2021 · Karl Lewis, Reinhard Dummer, et al. · Dermatology and Therapy · 20
PDF
Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months
2020 · Reinhard Dummer, John T. Lear, et al. · Journal of the American Academy of Dermatology · 18
PDF
Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
2023 · Lawrence F. Eichenfield, Adelaide A. Hebert, et al. · Journal of Drugs in Dermatology · 15
PDF
Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
2023 · Adelaide Hebert, Lawrence Eichenfield, et al. · Journal of Drugs in Dermatology · 12
PDF
Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone
2024 · Neal Bhatia, Lawrence F. Eichenfield, et al. · Journal of Drugs in Dermatology · 6
PDF
Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris
2023 · Lawrence F. Eichenfield, Linda Stein Gold, et al. · Journal of Drugs in Dermatology · 6
PDF
Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study
2021 · Anthony Andre, Nicholas Squittieri, et al. · Advances in Therapy · 6
PDF
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours
2020 · Darcy B. Pooler, Dylan B. Ness, et al. · British Journal of Clinical Pharmacology · 5
Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis
2025 · Zoe D. Draelos, Kizito Kyeremateng, et al. · Dermatology and Therapy · 4
PDF
Sonidegib reduced tumor burden in patients with advanced basal cell carcinoma in the BOLT trial: Long-term analysis results
2024 · Michael R. Migden, Aaron S. Farberg, et al. · EJC Skin Cancer · 4
PDF
Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants
2025 · Andrea Francesco Daniele Di Stefano, Milko Massimiliano Radicioni, et al. · Clinical Pharmacology in Drug Development · 3
PDF
Is There a Clinically Relevant Risk of Hyperkalemia with Topical Clascoterone Treatment?
2023 · James Del Rosso, Linda Stein Gold, et al. · PubMed Central · 3
PDF
Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma
2020 · Reinhard Dummer, Li Liu, et al. · Oncotarget · 3
PDF
Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study
2023 · John T Lear, Caroline Robert, et al. · European Journal of Dermatology · 2
PDF
Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study
2022 · Anthony Andre, Nicholas Squittieri, et al. · Endocrine Practice · 2
PDF
Notes & Comments on “Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and analysis”
2019 · Meagan Vogt, Anirudh Sethi, et al. · Journal of the American Academy of Dermatology · 2
Efficacy and safety of cosibelimab 800 mg every 2 weeks for locally advanced cutaneous squamous cell carcinoma: Updated follow-up from a pivotal study.
2026 · Eva Muñoz Couselo, Henri Montaudie, et al. · Journal of Clinical Oncology · 1
PDF
Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex
2026 · James Libecco, Lawrence F. Eichenfield, et al. · Journal of Drugs in Dermatology · 1
Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%
2025 · Zoe D. Draelos, Kizito Kyeremateng, et al. · Journal of Drugs in Dermatology · 1
42301 Efficacy and safety of clascoterone cream 1% in patients with acne vulgaris across subgroups defined by demographic characteristics
2023 · Lawrence F. Eichenfield, Adelaide A. Hebert, et al. · Journal of the American Academy of Dermatology · 1
Works count: 74
Citation count: 443
H-index: 9
I10-index: 9
Year
Topic
Type